This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Parkinson's Institute. Active years: 2015-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2016
Title: Innovations by Jeremy Nichols in Parkinson's Disease Research
Introduction
Jeremy Nichols is an accomplished inventor based in Sunnyvale, CA. He has made significant contributions to the field of Parkinson's disease research, holding 2 patents that focus on innovative assays to determine LRRK2 activity. His work is vital in understanding the mechanisms of Parkinson's disease and developing potential therapeutic strategies.
Latest Patents
Nichols' latest patents include an assay to determine LRRK2 activity in Parkinson's disease. This patent discloses novel phosphorylation sites identified in LRRK2 that are associated with Parkinson's disease. It also includes antibodies that specifically bind to these novel phosphorylation sites, along with laboratory and clinical uses thereof. This innovation is crucial for advancing research in the diagnosis and treatment of Parkinson's disease.
Career Highlights
Jeremy Nichols is currently affiliated with the Parkinson's Institute, where he continues to work on groundbreaking research. His dedication to understanding Parkinson's disease has positioned him as a key figure in the field. His contributions are not only recognized through his patents but also through his ongoing research efforts.
Collaborations
Nichols collaborates with notable professionals in the field, including his coworker Birgitt Schüle. Their combined expertise enhances the research efforts at the Parkinson's Institute, fostering an environment of innovation and discovery.
Conclusion
Jeremy Nichols is a prominent inventor whose work in Parkinson's disease research is paving the way for new diagnostic and therapeutic approaches. His patents and collaborations reflect his commitment to advancing the understanding of this complex disease.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile